{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016890","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.532374+00:00","generated_at":"2026-06-24T00:54:04.791130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"4D Molecular Therapeutics Q2 net loss widens to $28.1M; cash runway into 2025; expands 4D-310 trial to females","bullets":["Net loss of $28.1M in Q2 2022 vs $7.6M in Q2 2021; revenue fell to $0.2M from $14.6M.","Cash and equivalents of $261.6M as of June 30, 2022, expected to fund operations into first half 2025.","R&D expenses rose to $20.4M from $15.2M; G&A to $8.2M from $7.0M.","4D-310 Phase 1/2 expanded to include female Fabry patients; new steroid-sparing immunosuppression cohort added; data update expected 1H 2023.","Five clinical-stage candidates on track for multiple clinical data updates in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016890","json":"https://secwatch.observer/filing/0000950170-22-016890.json","markdown":"https://secwatch.observer/filing/0000950170-22-016890.md","text":"https://secwatch.observer/filing/0000950170-22-016890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017022016890/0000950170-22-016890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017022016890/fdmt-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:54:04.791130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}